Antiviral drug developer ContraVir Pharmaceuticals is working with ImageIQ on its Phase III program for a new shingles treatment, tapping the company for its imaging expertise. ContraVir's top prospect is FV-100, an oral nucleoside treatment designed to stamp out the varicella zoster virus and relieve shingles-associated pain. ImageIQ is on board to provide its imaging-enabled electronic data capture technology, helping investigators handle images of zoster rashes from the study's many sites to chart the drug's effect. More